Company Estrella Immunopharma, Inc.

Equities

ESLA

US2975841048

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
1 ^USD	-1.48%		-1.48%	-9.91%

May. 15	Estrella Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
Jan. 30	Estrella Immunopharma, Inc. announces an Equity Buyback for $1 million worth of its shares.	CI

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.

Managers	Title	Age	Since
Cheng Liu CEO	Chief Executive Officer	57	-
Jiandong Xu DFI	Director of Finance/CFO	54	-
Vicky Yang COO	Chief Operating Officer	52	-

Members of the board	Title	Age	Since
Cheng Liu CEO	Chief Executive Officer	57	-
Pei Xu BRD	Director/Board Member	42	-
Marsha Roberts BRD	Director/Board Member	55	-
Fan Wu BRD	Director/Board Member	51	-
Janelle Wu BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,376,293	10,536,637 ( 28.97 %)	0	28.97 %

Name	Equities	%	Valuation
Eureka Therapeutics, Inc. 69.04 %	25,277,831	69.04 %	26 M $
TradeuUP Acquisition Sponsor LLC 3.037 %	1,111,760	3.037 %	1 M $
Cheng Liu 0.8124 %	297,437	0.8124 %	309 334 $
Jiandong Xu 0.7222 %	264,388	0.7222 %	274 964 $
Jian Wei Li 0.3878 %	141,970	0.3878 %	147 649 $
UP FINTECH HOLDING LIMITED 0.3714 %	135,970	0.3714 %	141 409 $
Geode Capital Management LLC 0.1590 %	58,214	0.1590 %	60 543 $
ATW SPAC Management LLC 0.1093 %	40,000	0.1093 %	41 600 $
Hunting Hill Global Capital LLC 0.0583 %	21,358	0.0583 %	22 212 $
James Long 0.0273 %	10,000	0.0273 %	10 400 $

Name	Equities	%	Valuation
Highbridge Capital Management LLC -	413,517	-	21 916 $
Boothbay Fund Management LLC -	189,899	-	10 065 $
D.E. Shaw & Co., Inc. -	87,500	-	4 638 $
Walleye Capital LLC -	66,112	-	3 504 $
SkyView Investment Advisors LLC -	62,500	-	3 313 $
Yakira Capital Management, Inc. -	46,485	-	2 464 $
Whitebox Advisors LLC -	45,476	-	2 410 $
Walleye Trading LLC -	37,188	-	1 971 $
Cowen & Co. LLC -	28,597	-	1 516 $
Clear Street LLC -	28,591	-	1 515 $

Estrella Immunopharma, Inc.

5858 Horton Street Suite 370

94608, Emeryville

address Estrella Immunopharma, Inc.(ESLA)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ESTRELLA IMMUNOPHARMA, INC.	-9.91%	36.32M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs